Clinical trial
Study of SRF617 in Patients With Advanced Solid Tumors
NCT04336098
Study timeline
Study start (actual)2020-03-16Date precision: day
Registry last updated2024-06-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Solid Tumorunresolved
Interventions
SRF617DRUG
GemcitabineDRUG · verified · RxNorm: gemcitabine
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Mapped research locations
Los AngelesCalifornia, United States1DallasTexas, United States1TorontoOntario, Canada1San AntonioTexas, United States1SeattleWashington, United States1TampaFlorida, United States1MontrealQuebec, Canada1AuroraColorado, United States1CharlottesvilleVirginia, United States1DuarteCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04336098 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.